- Date 27 May 2020
Nuformix plc (LSE:NFX) (“Nuformix” or “the Company”), the pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs and VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system “CNS” diseases and disorders with high unmet need, today announced their agreement to develop novel cocrystal-based formulations of VistaGen’s CNS product candidates.
You might also be interested in these articles
Speechmatics and Puzzel partner to transform customer experiences using any-context speech recognition
Mon 6 Jul 2020
Speechmatics
Xaar celebrates 30 years as an industrial inkjet innovator
Mon 6 Jul 2020
Xaar plc
Beyond 2020: Heraeus offers solutions for semiconductors in AI, IoT and Big Data applications
Mon 6 Jul 2020
Heraeus Noblelight Ltd
